Navigation Links
The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
Date:12/1/2008

CHICAGO, Dec. 1 /PRNewswire-FirstCall/ -- The Female Health Company (Amex: FHC), which manufactures and markets the FC Female Condom(R), today reported record operating results for the quarter and fiscal year ended September 30, 2008.

For the three months ended September 30, 2008, net revenues increased 52% to $7.8 million, compared with $5.2 million in the quarter ended September 30, 2007. The Company reported net income attributable to common stockholders of $2.3 million, or $0.08 per diluted share, in the fourth quarter of FY2008, versus $1.1 million, or $0.04 per diluted share, in the corresponding period of the previous fiscal year.

In the fourth quarter of FY2008, the Company recorded a favorable currency gain of $0.9 million and a tax benefit of $0.2 million. Pretax income exclusive of currency gain totaled $1.3 million, an increase of 211% when compared with pretax income exclusive of currency loss of $0.4 million in the final quarter of FY2007.

Gross profit increased 73% to $3.5 million, or 44.8% of net revenues, in the most recent quarter, compared with $2.0 million, or 39.3% of net revenues, in the fourth quarter of FY2007. Operating income increased 206% to $1.2 million in the three months ended September 30, 2008, compared with $0.4 million in the corresponding period of the previous fiscal year. This was the first quarter in which the Company reported operating income in excess of $1 million.

The Company expects significant quarter-to-quarter variations in its operating results, due to the timing of large order receipts, production scheduling, and shipping of products.

For the year ended September 30, 2008, net revenues increased 33% to $25.6 million, compared with $19.3 million in FY2007. Gross profit increased 50% to $10.7 million, or 41.9% of net revenues, in FY2
'/>"/>

SOURCE The Female Health Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. The Female Health Company to Present at Rodman & Renshaw 10th Annual Global Investment Conference
2. The Female Health Company Reports Record Profit for Both Fourth Quarter and Fiscal Year 2007
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
5. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
6. Beckman Coulter to Present at Upcoming Healthcare Conferences
7. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
8. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
9. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
10. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
11. BioMarin to Present at the Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 Spartan Bioscience ... Spartan RX CYP2C19 System . It detects CYP2C19 genetic ... cheek swab. , The Spartan RX CYP2C19 System is ... has been approved in Canada. Due to the system’s ... may be used by healthcare professionals such as doctors, ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and the one-year ... of high volume High Pressure Processing (HPP) systems. , “We’re ... PackExpo this year, which is where we first announced the ... CEO at Avure. “Sales of the new Avure machine are ... challenges of market demand for higher throughput. We sold our ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... ET, LOS ANGELES, Aug. 31 Signalife, Inc. (Amex:,SGN), Lowell ... update since his matriculation into the Presidency,last month: 1. Dr. ... positions that were producing no revenue whatsoever and no ... Company, in his view. That was done ...
... Aug. 30 Cepheid (Nasdaq:,CPHD) will present at ... the Four Seasons Hotel, Boston, September 5 to ... Senior Vice President, Finance and,Chief Financial Officer, John ... on,September 7. The webcast, along with accompanying ...
... ON, Aug. 30 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... subsidiary, YM BioSciences USA,Inc. ("YM-USA") has been cleared ... initiate a Phase II trial investigating nimotuzumab in ...
Cached Biology Technology:Signalife Provides Corporate Update 2Signalife Provides Corporate Update 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 2YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 3YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 4YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer 5
(Date:10/29/2014)... 2014 — Cambridge, MA and Hebei, China — BGI ... high quality sequencing of the Jujube genome. Jujube is ... and the Jujube genome is particularly difficult to sequence ... factors. It is the first time that a genome ... study has been recently published in Nature ...
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... novel environment are linked to individual differences in ... completed at the University of Eastern Finland and ... study used novel, long-term observations of individual behaviour ... if behaviours predict the vulnerability to fishing in ... rearing environments. Based on the results, it ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3Fish 'personality' linked to vulnerability to angling 2
... is the primary component of nursery container substrates in ... widely used organic material is prompting researchers to investigate ... James E. Altland and Charles Krause of the USDA ... Development Center was designed to determine if ground switchgrass ...
... statistics buried within patient records or detailed in newspaper ... patterns, allowing the discovery of trends that were previously ... use of interactive maps and graphs, combined with word ... events like the spread of Swine flu," said Frank ...
... the Braunschweiger Helmholtz-Zentrums fr Infektionsforschung (Helmholtz Center for ... bacterial communities are able to support the degradation ... collaboration of thirteen partners from nine countries. Research ... today at the HZI. The significance of this ...
Cached Biology News:Switchgrass proves viable as nursery container substrate 2Switchgrass proves viable as nursery container substrate 3Visualization of geographic patterns may predict spread of disease 2Improving the degradation of toxic hydrocarbons 2
RABBIT ANTI AMPHOTERIN...
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
... by R. Edwards (1996) • ... types of immunoassays, including RIA, ... and on the photoluminescent and ... information is also given on ...
... contains the basic components required for the ... and recombinant Feline IL-10 in cell culture ... materials to run ELISAs on approximately fifteen ... are met: The assay is run ...
Biology Products: